Clinical Trials at University Medical Center New Orleans
As of August 2026, 51 paid clinical trials are recruiting at University Medical Center New Orleans, located at 1532 TULANE AVE, NEW ORLEANS, LA 70112-2860, phone (504) 903-3000 in New Orleans, Louisiana. Active studies at this site cover conditions such as Atrial Fibrillation, Hypertension and Malignant Solid Neoplasm. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
51 clinical trials at University Medical Center New Orleans
·Clear filters·Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
E-Mindfulness Approaches for Living After Breast Cancer
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Mobile Health for Adherence in Breast Cancer Patients
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Common conditions studied in New Orleans
- Atrial Fibrillation (8 active studies)
- Hypertension (7 active studies)
- Malignant Solid Neoplasm (7 active studies)
- Breast Cancer (6 active studies)
- Heart Failure (6 active studies)
- Cancer (5 active studies)
Leading research sponsors in New Orleans
- National Cancer Institute (NCI)
- Tulane University
- Children's Oncology Group
- Eli Lilly and Company
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in New Orleans?
There are approximately 405 recruiting clinical trials in New Orleans, Louisiana listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Orleans pay participants?
Most recruiting trials in New Orleans compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Orleans?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Orleans?
The most common conditions under active study in New Orleans include Atrial Fibrillation (8), Hypertension (7), Malignant Solid Neoplasm (7), Breast Cancer (6), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Orleans?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Orleans on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Orleans?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Orleans?
Recruiting research sites in New Orleans include University Medical Center New Orleans, Ochsner Medical Center Jefferson, Ochsner Clinic Foundation, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Orleans right now?
The largest active categories in New Orleans are Cancer & tumors (115), Cardiovascular (39), Neurology & pain (35). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University Medical Center New Orleans?
University Medical Center New Orleans is located at 1532 TULANE AVE, NEW ORLEANS, LA 70112-2860. Use the Google Maps link in the intro above to get directions.
How do I contact University Medical Center New Orleans?
You can reach University Medical Center New Orleans by phone at (504) 903-3000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.